Zydus' Saroglitazar Meets Primary Endpoint in Global Phase II(b) MASH Trial
Zydus Lifesciences announced that its drug Saroglitazar Magnesium met the primary endpoint in the global Phase II(b) EVIDENCES-X trial for Metabolic dysfunction Associated Steatohepatitis (MASH), a serious liver disease linked to metabolic disorders. The study, involving 189 patients over 52 weeks, showed resolution of steatohepatitis without worsening fibrosis and improvements in liver histology. The trial was led by experts from Indiana University and Virginia Commonwealth University, addressing significant unmet medical needs in MASH treatment.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 41/100.
Outlets measured: economictimes, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (58–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 31 Aug, 06:41 am. Other outlets followed.